The Tuberous Sclerosis Complex Research Program (TSCRP) is now accepting Pre-Applications for the fiscal year 2021 grant cycle.
Three award mechanisms are available this year:
-
Exploration – Hypothesis Development Award (up to $150,000 in direct costs over two years)
-
Idea Development Award (up to $500,000 in direct costs over three years)
-
Clinical Translational Research Award (up to $750,000 in direct costs over three years)
The deadline to submit a Pre-Application Letter of Intent is June 17, 2021 at 5 pm Eastern. A brief summary of the three award mechanisms and submission requirements can be found here.
Applications submitted to the FY21 TSCRP are encouraged to address one or more of the following Focus Areas:
-
Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
-
Preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with TSC-related seizures
-
Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological and behavioral interventions